Saudi Arabia Slashes Time To Market With Abridged Applications
Executive Summary
A new abridged drug review system in Saudi Arabia will dramatically cut the time it takes to get a new product to market in Saudi Arabia. The new system, which will go live in February 2017, could have a knock on effect on market access in neighboring markets.
You may also be interested in...
Revised Saudi Guide Addresses Frequent Questions On New Expedited Drug Registration Process
The Saudi FDA has issued four revised guidelines, including one on its recently-launched expedited process for registering new drugs and biologics based on the product’s prior approval in the US and the EU.
Saudi Arabia's Pharma Market Is 'Open For Business'
Growing market is also a gateway to the Gulf region, and Saudi regulators are developing an abridged review process for some drugs already reviewed by agencies such as FDA or EMA.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.